Geron +13%!!!!!!!!!!!!!! - 500 Beiträge pro Seite

[Börsenguru2001]

Wahnsinn +13%!
Gibt es hier vielleicht News?

[Lanzelotte]

Hi Börsenguru2001,

da interessiert sich ja wirklich noch einer für Geron. Bin selbst letzte Woche
eingestiegen. Es gab heute sogar 2 Meldungen zu Geron. Die kamen bei mir
allerdings nur über "Business Wire" rein.

In der ersten geht´s darum, dass das europäische Patentamt Geron ein Patent
zu Telomerase erteilt hat. Die nächste Meldung kommt gleich.


Thursday September 7, 7:35 am Eastern Time
Press Release
Geron Announces Grant of European Patent for Telomerase Activity Assays

MENLO PARK, Calif.--(BUSINESS WIRE)--Sept. 7, 2000--Geron Corporation
(Nasdaq:GERN - news) announced today that the European Patent Office has granted Geron a
patent covering telomerase activity assays. The grant of this patent brings Geron`s telomerase-related
portfolio to 45 issued or allowed U.S. patents and 13 granted foreign patents. In addition, Geron has
over 160 telomerase-related pending patent applications.

The patent, European Patent No. 0728207, includes 61 claims based on telomerase activity assays,
including Geron`s Telomeric Repeat Amplification Protocol (TRAP). Certain of the claims
specifically cover the methods of detecting telomerase activity in cells, including cancer cells. In
addition, the patent covers kits useful for detecting telomerase activity.

``Telomerase activity is a broadly applicable and highly specific marker for cancer,`` noted Calvin
Harley, Ph.D., Geron`s chief scientific officer. ``The assays covered by this patent provide a sensitive
test for telomerase activity and could be used in cancer prognosis and diagnosis, as well as for
monitoring the efficacy of therapeutic treatment regimens. There are also applications for monitoring
this enzyme during telomerase activation for the treatment of other age-related diseases.``

In collaboration with marketing partners, Geron has developed and commercialized ten
research-use-only assay kits that either detect telomerase activity or measure telomere length. In
addition, under license from Geron, Roche Diagnostics GmbH is currently conducting clinical studies
of assays for the diagnosis of cancer patients.

The newly granted European patent also includes claims for screening agents which modulate
telomerase activity. Since telomerase activity appears necessary (but not sufficient) for most cancers
to develop, there is much interest in the development of telomerase inhibitors as cancer therapeutics.
Geron is working in collaboration with its pharmaceutical partners, Pharmacia and Kyowa Hakko,
to identify telomerase inhibitors.

``This European patent further strengthens Geron`s intellectual property base of telomerase-related
patents,`` noted David J. Earp, Ph.D., J.D., Geron`s vice president of intellectual property. ``Geron
already has a number of issued U.S. patents for telomerase assays and cancer diagnosis based on
telomerase activity. Given the potential value of this technology, a strong international patent portfolio
is important and will contribute to the successful development of diagnostic tests and therapies for
human diseases.``

Geron is a biopharmaceutical company focused on discovering, developing and commercializing
therapeutic and diagnostic products for applications in oncology and regenerative medicine, and
research tools for drug discovery. Geron`s product development programs are based upon three
patented core technologies: telomerase, human pluripotent stem cells and nuclear transfer.

[Lanzelotte]

Und hier die zweite. Ungefährer Inhalt:
Geron kann einem Kapitalgeber in den nächsten 2 Jahre Aktien
für 50 Mill. $ verkaufen. Das gute daran: Geron kann die Aktien
mit einem geringen Abschlag zum jeweiligen Marktpreis verkaufen
und kann sich auch günstige Zeitpunkte (hoher Kurs) aussuchen.
Da Geron zur Zeit über 70 Mio.$ cash verfügt, aber im letzten halben
Jahr 20 Mio.$ verbrannt hat, ist das wohl ein wichtiger Schritt bezügl.
Finanzierung.

Thursday September 7, 7:32 am Eastern Time

Press Release

Geron Corporation Arranges $50
Million Equity Financing Facility

MENLO PARK, Calif.--(BW HealthWire)--Sept. 7, 2000--Geron Corporation (Nasdaq:GERN -
news) announced today that it has entered into a definitive agreement with Acqua Wellington North
American Equities Fund Ltd. (``Acqua Wellington``) for an equity financing facility covering the sale
of up to $50 million of the company`s common stock over the next 24 months.

This financing will be made pursuant to an effective shelf registration previously filed by Geron with
the Securities and Exchange Commission covering the sale of up to five million shares of its common
stock. These shares may be sold, at Geron`s discretion, at a small discount to market at the time of
sale. Geron will control the amount and timing of each sale of stock. Geron intends to use the
proceeds from the offering for general corporate purposes.

``Acqua Wellington has developed a flexible financing model. It allows a company to raise capital
efficiently when market conditions are favorable,`` stated David L. Greenwood, senior vice president
and chief financial officer.

Acqua Wellington Asset Management, LLC acts as an advisor to the Acqua Wellington Family of
Funds, which is targeted at investment opportunities among mid-cap and small-cap publicly traded
companies in domestic and global markets. Their primary focus is in the life science and technology
sectors.

Geron is a biopharmaceutical company focused on discovering, developing and commercializing
therapeutic and diagnostic products for application in oncology and regenerative medicine, and
research tools for drug discovery. Geron`s product development programs are based upon three
patented core technologies: telomerase, human pluripotent stem cells and nuclear transfer.

[Lanzelotte]

Aus folgenden Gründen ist Geron für mich klarer
Favorit in diesem Segment.

1. Außer in der Stammzellenforschung ist Geron auch in dem
...Bereich der Telomere tätig - diesbezüglich auch das Patent.
...Telomere sitzen wie Kappen über den menschlichen Chromosomen
...und wachen darüber, wie oft sich eine Zelle teilen kann.

2. Auch in der Klontechnologie ist Geron tätig. 1999 wurde das schottische
....Roslin Institute übernommen (Stichwort Klonschaf Dolly).

3. Bestehende Allianz mit dem Genforschungsunternehmen Celera.

Gruss
Lanze

[surfinstocks]

Viel wichtiger!

Die Telomer regulieren wie oft sich eine Zelle teilen kann, sie regulieren also das Zellalter. Jede menschliche Zelle kann praktisch sich 60 bis 80 Mal teilen, dann sind die Telomer verbraucht. Falls man sie verlängern kann, kann sich die Zelle wieder teilen.

Revolution!!!!!!!!!!!!!!!!!!!!!!

Alte Menschen habe z.B. Telomer mit der Länge 5, junge Menschen haben Länge 10. Folge: Wunden von alten Menschen heilen langsamer(weil sich nicht so viele Zellen wie früher bei Telomerlänge 10) teilen können. Nach Jeder Zellteilung verringert sich das Telomer. falls Geron es schafft die Telomer zu verlängern(was Krebs auch schafft), können sich die Zellebn wieder öfter teilen.

Dieses Verjüngungsprogramm läuft schon von Natur aus im mänlichen Hodensack, Männer können unendlich viel Sperma produzieren. Es funktioniert schon im menschlich Körper!

Wirtschaftlichkeit:

Blut von alten Menschen kann verjüngt werden durch Telomerverlängerung
Immunsystem kann verbessert werden
Ein höheres Alter kann erreicht werden

Die Unsterblichkeit kann man leider noch nicht ermöglichen, da die ganze Sache ziemlich komplex ist und das menschliche Gehirn ziemlich problematisch ist.

[windelwinni]

Hallo zusammen,

hier die Quartalsergbnisse:

Geron Corporation Reports 2000 Third Quarter Financial Results and Events
Friday, November 10, 2000 07:40:18 AM - Business Wire

MENLO PARK, Calif., Nov 10, 2000 (BW HealthWire) -- Geron Corporation (Nasdaq:GERN)
today reported financial results and events for the three and nine months ended September 30,
2000.

For the quarter, the company reported operating revenue of $1.8 million and operating expenses of
$8.1 million compared to $1.3 million and $8.2 million, respectively, for the comparable period in
1999. Net loss for the period was $4.9 million or $(0.23) per share compared to $6.9 million or
$(0.42) per share in 1999. For the nine months ended September 30, 2000, the company reported
operating revenue of $4.8 million and operating expenses of $26.7 million compared to $4.1 million
and $42.9 million, respectively, for the comparable 1999 period. Net loss for the nine month period
was $29.9 million or $(1.45) per share compared to $38.4 million or $(2.55) per share in 1999.

Revenues recognized during the third quarter of 2000 include research support payments under the
Pharmacia and Kyowa Hakko collaborative agreements and royalties received under various
diagnostic and research products licensing agreements.

Excluding the effect of the acquisition expense in 1999, operating expenses for the nine months
ended September 30, 2000 have increased compared to the comparable periods in 1999.
Research and development expenses increased primarily as a result of research funding at the
Roslin Institute. General and administrative expenses increased as a result of consulting contracts
and increased accounting and legal costs relating to various transactions.

In September 2000, the company entered into an agreement with an institutional investor for an
equity financing facility covering the sale of up to $50.0 million of the company`s common stock
over 24 months. The company controls the amount and timing of each sale of stock.

Geron is a biopharmaceutical company focused on discovering, developing and commercializing
therapeutic and diagnostic products for applications in oncology, drug discovery and regenerative
medicine. Geron`s product development programs are based upon three patented core
technologies: telomerase, human pluripotent stem cells and nuclear transfer.

The company desires to take advantage of the "safe harbor" provision of the Private Securities
Litigation Reform Act of 1995. Specifically, the company wishes to alert readers that the matters
discussed in this press release may constitute forward-looking statements that are subject to certain
risks and uncertainties, including risks inherent in research and development efforts, reliance on
collaborative partners, enforcement of patents and proprietary rights, need for future capital,
potential competition and uncertainty of regulatory approvals or clearances. Actual results may
differ materially from the results anticipated in these forward-looking statements. Additional
information on potential factors that could affect the company`s financial results is included in the
company`s Quarterly Report on Form 10-Q for the quarter ended September 30, 2000.

Contact: Geron Corporation Olivia K. Bloom Controller 650-473-7700

To receive an index and copies of recent press releases, call Geron`s News on Demand toll-free
fax service, 1-800-782-3279. Additional information about the company can be obtained at
www.geron.com